Sign In  |  Register  |  About San Rafael  |  Contact Us

San Rafael, CA
September 01, 2020 1:37pm
7-Day Forecast | Traffic

  • Search Hotels in San Rafael

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Syndax Pharma (NQ: SNDX )

16.86 +0.77 (+4.82%)
Streaming Delayed Price Updated: 3:53 PM EST, Nov 25, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Syndax Pharma

< Previous 1 2 3 4 Next >
Benzinga's Top Ratings Upgrades, Downgrades For April 11, 2022
Upgrades 
Via Benzinga
Do Penny Stocks Ever Make Money? Here Are 7 Success Stories
Penny stocks can make money. Success stories include Advanced Micro Devices, a former penny stock that earned a $3.2 billion net income in 2021. Here are six others. 
Via InvestorPlace
Earnings Scheduled For March 1, 2022
Companies Reporting Before The Bell • Precigen (NASDAQ:PGEN) is expected to report earnings for its fourth quarter. • TG Therapeutics (NASDAQ:TGTX) is estimated... 
Via Benzinga
The Week Ahead In Biotech (Aug. 8-14): Jazz Pharma FDA Decision, Earnings Deluge and IPOs In The Spotlight
Biopharma stocks ended higher for the week ending Aug. 6, as the sector latched on to the optimism that was evident in the broader markets. Earnings continued to flow in,... 
Via Benzinga
Exposures Product Safety
Syndax Pharmaceuticals's Return On Capital Employed Overview
According to Benzinga Pro, during Q4, Syndax Pharmaceuticals (NASDAQ:SNDX) earned $96.20 million, a 566.1% increase from the preceding quarter. Syndax Pharmaceuticals also posted... 
Via Benzinga
Recap: Syndax Pharmaceuticals Q4 Earnings
Syndax Pharmaceuticals (NASDAQ:SNDX) reported its Q4 earnings results on Tuesday, March 1, 2022 at 04:00 PM. Here's what investors need to know about the announcement.... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For February 15, 2022
Upgrades For Blue Bird Corp (NASDAQ:BLBD), Roth Capital upgraded the previous rating of Neutral to Buy. Blue Bird earned $0.07 in the first quarter, compared to $0.00 in the year-... 
Via Benzinga
The Daily Biotech Pulse: Sanofi, Bristol-Myers Squibb Gain On Earnings, Valneva-Pfizer Tout Positive Lyme Disease Vaccine Data, UNITY Biotech Restructures
Here's a roundup of top developments in the biotech space over the last 24 hours. 
Via Benzinga
The Daily Biotech Pulse: Allakos Slips Negative Late-Stage Data, Pfizer & Merck Announce Fresh COVID Pill Deal With UK, Regulatory Setback For Takeda
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Allakos's Lirentelimab Flunks Late-Stage Studies In Patients With... 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Gainers Calliditas Therapeutics (NASDAQ:CALT) stock rose 41.09% to $26.3 during Thursday's pre-market session. The market value of their outstanding shares is at $688.... 
Via Benzinga
The Daily Biotech Pulse: Calliditas Snags FDA Nod, Novartis to Buy Back $15B In Shares, Valneva Touts Vaccine Data, Immix, Bionomics Debut On Wall Street
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Calliditas Gets Conditional Approval For Kidney Inflammation Disease Drug... 
Via Benzinga
Syndax Pharma Posts Additional Data On Clinical Activity, Responses From Early-Stage Leukemia Trial
Syndax Pharmaceuticals Inc (NASDAQ: SNDX) revealed updated data from the Phase 1 dose-escalation portion of the AUGMENT-101 trial of SNDX-5613 in patients with... 
Via Benzinga
The Week Ahead In Biotech (Nov. 14-Nov. 20): BioMarin FDA Decision, Tapering Earnings News Flow, Conference Presentations And More
Biotech stocks declined for the second straight week amid a broader market pullback, along with earnings news from small- and micro-cap companies and presentations at... 
Via Benzinga
Exposures Product Safety
Earnings Preview For Syndax Pharmaceuticals
Syndax Pharmaceuticals (NASDAQ:SNDX) is set to give its latest quarterly earnings report on Monday, 2021-11-15. Here's what investors need to know before the announcement.... 
Via Benzinga
Earnings Scheduled For November 15, 2021
Companies Reporting Before The Bell • Sohu.com (NASDAQ:SOHU) is estimated to report earnings for its third quarter. • Tyson Foods (NYSE:TSN) is estimated to... 
Via Benzinga
81 Biggest Movers From Yesterday
Gainers Evaxion Biotech A/S (NASDAQ: EVAX) shares jumped 95.1% to close at $12.68 on Thursday after dropping over 10% on Wednesday. TDH Holdings, Inc. (NASDAQ: PETZ) jumped 79.8... 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
Gainers Evaxion Biotech (NASDAQ:EVAX) stock moved upwards by 157.5% to $16.74 during Thursday's regular session. Evaxion Biotech's stock is trading at a volume of... 
Via Benzinga
55 Stocks Moving In Thursday's Mid-Day Session
Gainers Evaxion Biotech A/S (NASDAQ: EVAX) shares climbed 179% to $18.17 after dropping over 10% on Wednesday. NerdWallet, Inc. (NASDAQ: NRDS) jumped 60% to $28.86 after the... 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Gainers Ocugen (NASDAQ:OCGN) shares moved upwards by 11.11% to $7.5 during Tuesday's pre-market session. The market value of their outstanding shares is at $1.4... 
Via Benzinga
The Daily Biotech Pulse: Eisai, Biogen Pursue Approval Of Second Alzheimer's Treatment; Sanofi Changes mRNA Strategy; GSK Subsidiary To Develop Long-Acting HIV Preventive
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 27) Acceleron Pharma Inc. (... 
Via Benzinga
Syndax Pharma, Incyte Ink Licensing Pact For Graft Vs. Host Disease Candidate
Syndax Pharmaceuticals Inc (NASDAQ: SNDX) and Incyte Corporation (NASDAQ: INCY) have entered into an exclusive worldwide collaboration and license... 
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
Gainers Syndax Pharmaceuticals (NASDAQ:SNDX) shares moved upwards by 8.94% to $20.48 during Monday's pre-market session. The company's market cap stands at $995.9... 
Via Benzinga
Syndax Pharmaceuticals's Return On Capital Employed Insights
According to data from Benzinga Pro, during Q2, Syndax Pharmaceuticals's (NASDAQ:SNDX) reported sales totaled $379.00 thousand. Despite a 17.78% increase in earnings, the... 
Via Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
Gainers IVERIC bio (NASDAQ:ISEE) shares ... 
Via Benzinga
44 Stocks Moving In Monday's Mid-Day Session
Gainers Intellia Therapeutics, Inc. (NASDAQ: NTLA) shares climbed 43.5% to $127.44 after the company announced positive clinical data for its CRISPR therapy. Marin Software... 
Via Benzinga
Earnings Scheduled For August 9, 2021
Companies Reporting Before The Bell • Privia Health Group (NASDAQ:PRVA) is projected to report quarterly loss at $1.57 per share on revenue of $215.17 million. •... 
Via Benzinga
Syndax Pharmaceuticals: Return On Capital Employed Insights
In Q1, Syndax Pharmaceuticals (NASDAQ:SNDX) posted sales of $379.00 thousand. Earnings were up 36.77%, but Syndax Pharmaceuticals still reported an overall loss of $27.16 million... 
Via Benzinga
Return On Capital Employed Overview: Syndax Pharmaceuticals
In Q1, Syndax Pharmaceuticals (NASDAQ:SNDX) posted sales of $379.00 thousand. Earnings were up 36.77%, but Syndax Pharmaceuticals still reported an overall loss of $27.16 million... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For May 25, 2021
Upgrades For Appian Corp (NASDAQ:APPN), Macquarie upgraded the previous rating of Underperform to Neutral. For the first quarter, Appian had an EPS of $0.06, compared to... 
Via Benzinga
Syndax Pharma Updates On Interim Phase 1 Data From SNDX-5613 Leukemia Trial
Syndax Pharmaceuticals Inc (NASDAQ: SNDX), in its Q1 earnings, also announced new data from the ongoing Phase 1 dose-escalation portion of the Phase 1/2... 
Via Benzinga
< Previous 1 2 3 4 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 SanRafael.com & California Media Partners, LLC. All rights reserved.